Marshall Wace North America’s MediciNova MNOV Stock Holding History

Marshall Wace North America’s Portfolio MNOV Stock Details MNOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$45K	Buy	+11,800	New	+$44.8K	﹤0.01%	1382

Other funds holding MNOV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Marshall Wace North America's MNOV Position: Q3 2021 in Review

Marshall Wace North America opened a new position in MediciNova (MNOV) in Q3 2021: 11,800 shares worth $45K. The stake represents ﹤0.01% of the portfolio and ranks #1382 among its holdings.

39 funds tracked by Wall St. Rank hold MNOV as of Q3 2021.

Marshall Wace North America held 11,800 shares of MediciNova worth $45K as of Q3 2021.
MediciNova was a new Marshall Wace North America position in Q3 2021.
MediciNova made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1382 holding.
39 funds tracked by Wall St. Rank held MediciNova as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.